Abstract
Introduction Multiple Sclerosis (MS) is a debilitating neurodegenerative disease in which demyelination due to auto-inflammation is considered to be the underlying pathogenesis, though the exact etiology is not known. Most of the management strategies involve medications that are anti-inflammatory or immune-suppressive, which do have associated side effects. In this study we have evaluated in MS patients, the clinical effects of a novel beta-glucan which has a track record of anti-inflammatory, immune-modulating potentials in earlier clinical and pre-clinical studies.
Method The study involved 12 MS patients who consumed two sachets of N-163 strain of Aureobasidium pullulans produced B-Glucan, daily for 60 days along with routine medication.
Results The Expanded Disability Status Scale (EDSS) improved by 0.5 in two patients and by 1 in one patient post-intervention, worsened in 1 patient, remaining stable in the rest. Decrease in IL-6, improvement in CD4+ve, CD19+ve, CD3+ve, and CD8+ ve cell count, increase in Lymphocyte to C-reactive protein ratio (LCR), Leukocyte to CRP ratio (LeCR) and a decrease in Neutrophil to Lymphocyte ratio (NLR) were observed.
Conclusion This study having proven the safety of N-163 strain of A.pullulans produced B-Glucan food supplement and the efficacy by improvement in the EDSS score, besides beneficial modulation of inflammation and immune parameters of relevance in MS patients in a short duration of 60 days, has significant potential as a disease modifying adjuvant in MS. Immunological parameters like NLR, LCR, LeCR correlating with clinical improvement, in line with earlier reports using the same beta-glucans, gain further significance for their potentials as biomarkers in MS.
Competing Interest Statement
Author Samuel Abraham is a shareholder in GN Corporation, Japan which holds shares of Sophy Inc., Japan., the manufacturers of novel beta glucans using different strains of Aureobasidium pullulans; a board member in both the companies and also an inventor to several patents of relevance to these beta glucans.
Clinical Trial
CTRI/2022/05/042497
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was registered in Clinical trials registry of India, CTRI/2022/05/042497 and approved by Universal Ethics Committee (A Unit of Aurous HealthCare Research and Development India Pvt. Ltd).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Declarations:
Ethics approval and consent to participate The study was registered in Clinical trials registry of India, CTRI/2022/05/042497 and approved by Universal Ethics Committee (A Unit of Aurous HealthCare Research and Development India Pvt. Ltd).
Consent for publication Not applicable
Availability of data and material All data generated or analysed during this study are included in the article itself.
Funding No external funding was received for the study
Competing interests Author Samuel Abraham is a shareholder in GN Corporation, Japan which holds shares of Sophy Inc., Japan., the manufacturers of novel beta glucans using different strains of Aureobasidium pullulans; a board member in both the companies and also an inventor to several patents of relevance to these beta glucans.
(drddp{at}nichimail.jp)
(drvetri{at}bewellhospitals.com)
(nikewaki{at}phoenix.ac.jp)
(kcy{at}nichimail.jp)
(lb-20yamamoto{at}hospk.ncgm.go.jp)
(h-kawashima{at}chiba-u.jp)
(drsudhakar77{at}gmail.com)
(masala76{at}gmail.com)
(rsk{at}nichimail.jp)
(drspp{at}nichimail.jp)
(drsam{at}nichimail.jp)
Figures have been modified to gray-scale
Data Availability
All data produced in the present work are contained in the manuscript
